The microbiome is the community of microorganisms living in and on the body. Researchers are studying whether changes in the microbiome may influence immune regulation and inflammatory diseases such as sarcoidosis. This is an evolving field: research findings do not yet provide a routine diagnostic test or a proven treatment. Discuss any proposed supplement, diet or treatment change with a qualified healthcare professional.
Sarcoidosis and the lung microbiota
The article “Studio indaga possibile ruolo del microbiota polmonare” explores the possible role of the lung microbiota in people with sarcoidosis.
For better understanding:
The microbiota is the range of microorganisms that may be commensal, symbiotic or pathogenic and that live in and on all multicellular organisms, including plants. The microbiota includes bacteria, archaea, protists, fungi and viruses, and has been found to be essential for the immune, hormonal and metabolic homeostasis of their host.
The role of the lung microbiota in sarcoidosis is still poorly studied.
The aim of the study was to investigate the pulmonary fungal and bacterial populations of subjects with sarcoidosis compared with healthy controls, and their associations with antimicrobial peptides.
Conclusions
Patients with sarcoidosis have a different bacterial and fungal profile in the lungs, with lower concentrations of antimicrobial peptides, suggesting an interaction between the microbiota and the innate immune system. It remains to be confirmed whether dysbiosis is a pathogenic mechanism.
The pulmonary bacterial and fungal microbiota of patients with sarcoidosis is altered compared with healthy controls. But there is more: in addition to dysbiosis, there is lower expression of antimicrobial peptides, suggesting a possible link with the immune system. However, whether these changes should be considered part of the pathological mechanism remains to be determined.
This is the conclusion of a study by Kristel S. Knudsen and colleagues at the University of Bergen (Norway), recently published in Microbiome.
Although any organ can be affected, the lungs are the main target. Among the varied and uncertain possible causes, an altered microbiome may also have a role, although studies in this area remain scarce.
Antimicrobial peptides and proteins (AMPs) are key elements of the innate immune system’s defence against respiratory pathogens. To investigate this, the researchers included 35 patients with sarcoidosis and 35 healthy controls, comparing bacterial and fungal profiles and AMP concentrations in oral wash (OW) fluid and protected bronchoalveolar lavage (PBAL) fluid.
Findings from the study
The taxonomic profiles showed that fungal and bacterial composition differed by group and sample type (oral wash or alveolar lavage), at class and genus levels.
In particular:
Among fungal classes, Saccharomycetes were the most abundant in OW samples from both groups and in PBAL samples from controls.
In patients’ PBAL samples, the taxa showed a broader distribution, with more Eurotiomycetes and Malasseziomycetes.
Candida was the most abundant genus in OW samples regardless of group, but was less abundant in patients’ PBAL samples than in those of controls.
Aspergillus, by contrast, showed its greatest abundance in patients’ PBAL samples and was almost undetectable in controls.
Lower levels of Saccharomycetes were reported in PBAL samples, and of Sordariomycetes in patients’ OW samples.
Firmicutes and Bacteroidetes were reported as the dominant genera, with Streptococcus, Prevotella and Veillonella as genera in both groups.
Abscondibacteria were significantly lower in patients’ PBAL samples and Fusobacteria in patients’ OW samples; Stomatobacteria and Synergistia were significantly higher.
Comparison of microbial diversity
1. Fungal alpha diversity showed no significant differences between groups, whereas beta diversity differed in OW and PBAL samples.
2. Bacterial diversity was significantly reduced in patients.
Finally, the source reports significantly lower antimicrobial peptide and protein values in patients, although no correlation emerged with microbial alpha diversity or antibacterial components such as Hbd-1/2 or SPL1.
Conclusions
This study therefore showed differences in bacterial and fungal diversity between patients with sarcoidosis and controls, as well as differences in antimicrobial peptide levels in the lower airways.
Respiratory microbiota dysbiosis appears to be involved in disease processes, although whether it is a cause or a consequence remains to be established.
Source:
https://microbioma.it/pneumologia/sarcoidosi-studio-indaga-possibile-ruolo-del-microbiota-polmonare/